Tango Therapeutics (TNGX) Other financing activities (2020 - 2026)

Tango Therapeutics' Other financing activities history runs 6 years deep, the most recent figure standing at $17.6 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 880150.0% year-over-year to $17.6 million in Q1 2026; TTM through Mar 2026 was $17.9 million, a 3969.16% increase from a year earlier, with the FY2023 full-year figure at $689000.0, changed N/A from the prior year.
• Other financing activities advanced to $17.6 million in Q1 2026 per TNGX's latest filing, from $2000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $17.6 million in Q1 2026 and bottomed at $2000.0 in Q1 2025.
• The 4-year median for Other financing activities is $169000.0 (2022), against an average of $4.5 million.
• Across the five-year window, Other financing activities plunged 72.45% in 2023 and jumped 880150.0% in 2026, its largest moves.
• Year by year, Other financing activities stood at $265000.0 in 2022, then tumbled by 72.45% to $73000.0 in 2023, then tumbled by 97.26% to $2000.0 in 2025, then soared by 880150.0% to $17.6 million in 2026.
• Per Business Quant, the three latest TNGX Other financing activities figures stand at $17.6 million (Q1 2026), $2000.0 (Q1 2025), and $73000.0 (Q1 2023).